Wśród nich znalazło się 8 abstraktów prezentowanych przez członków PLRG, w tym jeden przygotowany przez Grupę Roboczą Chłoniaków Hodgkina: 357. „Short (x3) nivolumab before BGD chemotherapy improves the remission rate in relapsed/refractory Hodgkin Lymphoma: N-BURGUND trial of the Polish Lymphoma Research Group”.
- Prof. dr hab. Jan Maciej Zaucha
357 “Short (x3) nivolumab before BGD chemotherapy improves the remission rate in relapsed/refractory Hodgkin Lymphoma: N-BURGUND trial of the Polish Lymphoma Research Group”
J.M. Zaucha, E. Paszkiewicz-Kozik, M. Taszner, B. Małkowski, J. Rybka, K. Chromik, A. Kołkowska-Leśniak, E. Subocz,Ł. Targoński, P. Ceklarz, M. Witkowska, K. Domańska-Czyż, A. Giza, M. Kobylecka, C-A. Voltin, J. Romejko-Jarosińska, B. Ostrowska, M. Świerkowska, A. Druzd-Sitek, M. Kurlapski, M. Bednarek, G. Romanowicz, J. Góra-Tybor, J. Hałka, T. Wróbel, R.Swoboda, S. Giebel, G. Helbig, E. Lech-Marańda
- Prof. dr hab. Wojciech Jurczak
235 “Nemtabrutinib in Relapsed or Refractory Follicular Lymphoma: Updated Results From Cohort G of the Phase 2 BELLWAVE-003 Study”
359 “Updated Results From KEYNOTE-B68: Pembrolizumab Every 6 Weeks in Participants with Relapsed or Refractory Classic Hodgkin Lymphoma or Primary Mediastinal B-cell Lymphoma”
433 “Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed/Refractory Lymphoid Malignancies: Updated Analysis”
- Dr Elżbieta Wojciechowska-Lampka
355 “Efficacy and Safety of the EVA Chemotherapy Regimen in Pregnant Patients with Hodgkin’s Lymphoma: A Long-Term Outcome Analysis”
- Dr Kateryna Filonenko
411 “The search for baseline imaging predictive factors of refractoriness to ABVD in the low and very low risk patients with early stages HL of the RAFTING trial”
- Dr Marta Bednarek
417 “TMTV < than 32,5 ml impairs the successful detection of ctDNA in early-stage Hodgin lymphoma patients – the preliminary report from the RAFTING trial”
- Dr Anna Dąbrowska-Iwanicka
64 Nivulomab + GemOx as second-line therapy for peripheral T cell lymphoma in transplant-ineligible patients: final analysis of a sub-cohort of the randomized niveau trial”
Pełen program Konferencji znajduje się na stronie: https://www.icml.ch/icml/congresses/18-icml/Scientific-Programme.html
